• 22-85 years of age.

• English speaking participants. Spanish-only speakers may be included in the future at select sites appropriately translated.

• History of non-permanent atrial fibrillation.

• CHA2DS2-VASC score of 1-4 for men and 2-4 for women without prior stroke or Transient Ischemic Attack (TIA), The CHA2DS2-VASc score is a point-based system used to stratify the risk of stroke in Atrial Fibrillation (AF) patients. The acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female). Congestive heart failure defined as: The presence of signs and symptoms of either right (elevated central venous pressure, hepatomegaly, dependent edema) or left ventricular failure (exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, pulmonary venous congestion) or both, confirmed by non-invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction and/or ejection fraction \< 40%.

• The participant is on a DOAC at the time of screening and willing to stay on DOAC for duration of study.

• Willing and able to comply with the protocol, including:

‣ Possession of a smart watch-compatible smart phone (iPhone that supports the latest shipping iOS) with a cellular service plan

⁃ Be willing to wear the smart watch for the suggested minimum of 14 hours a day

⁃ Expected to be within cellular service range at least 80% of the time

• Willing and able to discontinue DOAC

• The participant is willing and able to provide informed consent.